Published in Lancet on January 04, 1975
Social class and coronary heart disease. Br Heart J (1981) 5.43
Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. BMJ (1991) 4.35
Insulin resistance and cardiovascular disease. J Clin Invest (2000) 4.05
Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest (2006) 3.76
Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. Br Heart J (1988) 3.05
The detection of linkage disequilibrium between closely linked markers: RFLPs at the AI-CIII apolipoprotein genes. Am J Hum Genet (1988) 2.85
Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci U S A (1997) 2.59
In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A (1993) 2.39
A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest (1980) 2.27
Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest (1996) 2.10
Diets containing sea cucumber (Isostichopus badionotus) meals are hypocholesterolemic in young rats. PLoS One (2013) 2.01
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
James Mackenzie Lecture 1979. The happiness pill? J R Coll Gen Pract (1980) 1.76
The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay. J Clin Invest (1977) 1.75
Lipid profile components and risk of ischemic stroke: the Northern Manhattan Study (NOMAS). Arch Neurol (2009) 1.74
High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. Br Med J (Clin Res Ed) (1986) 1.73
Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I. J Clin Invest (1978) 1.69
Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation (2013) 1.65
Interaction between high density and low density lipoproteins uptake and degradation by cultured human fibroblasts. J Clin Invest (1977) 1.58
Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet (1981) 1.54
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest (1982) 1.54
Metabolic fate of chylomicron phospholipids and apoproteins in the rat. J Clin Invest (1979) 1.52
High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J (1978) 1.50
Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest (1996) 1.49
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest (2001) 1.47
Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep (2010) 1.46
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol (2005) 1.43
Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest (1994) 1.42
Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet (1988) 1.42
Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest (1991) 1.42
Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest (1989) 1.40
A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest (1990) 1.37
Effects of high dietary sugar. Br Med J (1980) 1.37
Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest (1999) 1.35
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes (2015) 1.33
Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum (2009) 1.31
The role of apolipoprotein AI domains in lipid binding. Proc Natl Acad Sci U S A (1996) 1.30
A genomewide search using an original pairwise sampling approach for large genealogies identifies a new locus for total and low-density lipoprotein cholesterol in two genetically differentiated isolates of Sardinia. Am J Hum Genet (2004) 1.24
Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum (2012) 1.20
A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur J Epidemiol (1998) 1.20
The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J (1996) 1.19
Prevalence of ischaemic heart disease and associations with serum lipoproteins in subjects aged 45 to 64 years. The Speedwell study. Br Heart J (1982) 1.19
Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. Curr Opin Lipidol (2009) 1.18
Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. Proc Natl Acad Sci U S A (2010) 1.18
Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem (2010) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2008) 1.16
Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest (1990) 1.16
The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota. II. Regression relationships with concomitants. Am J Hum Genet (1992) 1.16
Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis (1991) 1.15
Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. J Clin Invest (1984) 1.14
Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest (1992) 1.11
High-density and low-density lipoproteins and prevalence of vascular disease in diabetes mellitus. Br Med J (1978) 1.09
Human pedigree-based quantitative-trait-locus mapping: localization of two genes influencing HDL-cholesterol metabolism. Am J Hum Genet (1999) 1.08
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res (2009) 1.08
Evidence of health benefits of canola oil. Nutr Rev (2013) 1.08
Cholesterol testing. BMJ (1989) 1.07
Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest (1988) 1.07
High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest (1987) 1.07
Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest (1979) 1.06
Topical timolol and serum lipoproteins. Br J Ophthalmol (1990) 1.04
The effects of weight loss by exercise or by dieting on plasma high-density lipoprotein (HDL) levels in men with low, intermediate, and normal-to-high HDL at baseline. Metabolism (1994) 1.03
Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest (1993) 1.03
Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res (2010) 1.03
Glucocorticoid inhibition of vascular smooth muscle cell proliferation: influence of homologous extracellular matrix and serum mitogens. J Cell Biol (1984) 1.03
Glycine dimerization motif in the N-terminal transmembrane domain of the high density lipoprotein receptor SR-BI required for normal receptor oligomerization and lipid transport. J Biol Chem (2011) 1.02
The lipoproteins: predictors, protectors, and pathogens. Br Med J (Clin Res Ed) (1983) 1.02
Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler Thromb Vasc Biol (2012) 1.01
Correlative study between neuron-specific enolase and blood sugar level in ischemic stroke patients. J Neurosci Rural Pract (2011) 1.01
Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. Proc Natl Acad Sci U S A (2011) 1.01
Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population. Can Med Assoc J (1980) 1.00
Characterization of high density lipoproteins in patients heterozygous for Tangier disease. J Clin Invest (1977) 1.00
High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis (2013) 1.00
A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. Am J Hum Genet (1990) 1.00
Changes in blood lipids and blood pressure during adolescence. Br Med J (1980) 0.98
Metabolism of the serum amyloid A proteins (SSA) in high-density lipoproteins and chylomicrons of nonhuman primates (vervet monkey). Am J Pathol (1983) 0.96
Loss of PDZK1 causes coronary artery occlusion and myocardial infarction in Paigen diet-fed apolipoprotein E deficient mice. PLoS One (2009) 0.96
The effect of ABCA1 gene polymorphisms on ischaemic stroke risk and relationship with lipid profile. BMC Med Genet (2007) 0.96
Plasma lipids in premenopausal women with mammographic dysplasia. Br J Cancer (1989) 0.95
High density lipoprotein and coronary heart disease. BMJ (1989) 0.95
Alcohol consumption and its relation to cardiovascular risk factors in British women. BMJ (1992) 0.94
Structure of apolipoprotein A-I N terminus on nascent high density lipoproteins. J Biol Chem (2010) 0.94
Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest (1994) 0.94
Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem (2010) 0.93
Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier). J Clin Invest (1982) 0.93
Microvesicles: potential markers and mediators of endothelial dysfunction. Curr Opin Endocrinol Diabetes Obes (2012) 0.93
Carotid intima media thickness and low high-density lipoprotein (HDL) in South Asian immigrants: could dysfunctional HDL be the missing link? Arch Med Sci (2014) 0.92
Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc (2012) 0.92
Kinetic parameters for high density lipoprotein apoprotein AI and cholesteryl ester transport in the hamster. J Clin Invest (1997) 0.92
Lipoprotein subfractions of runners and sedentary men. Metabolism (1986) 0.92
Molecular belt models for the apolipoprotein A-I Paris and Milano mutations. Biophys J (2000) 0.91
Extracellular hydrophobic regions in scavenger receptor BI play a key role in mediating HDL-cholesterol transport. Arch Biochem Biophys (2010) 0.90
Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Invsestigators. J Clin Invest (1998) 0.90
On the heritability of serum high density lipoprotein in twins. Am J Hum Genet (1980) 0.90
Genetic variant of V825I in the ATP-binding cassette transporter A1 gene and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis (2011) 0.90
Managing hyperlipidaemias. Br Med J (Clin Res Ed) (1982) 0.90
Relationship of drinking water disinfectants to plasma cholesterol and thyroid hormone levels in experimental studies. Proc Natl Acad Sci U S A (1986) 0.90
Contributions of a disulfide bond and a reduced cysteine side chain to the intrinsic activity of the high-density lipoprotein receptor SR-BI. Biochemistry (2012) 0.89
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet (1986) 6.51
Radical SAM, a novel protein superfamily linking unresolved steps in familiar biosynthetic pathways with radical mechanisms: functional characterization using new analysis and information visualization methods. Nucleic Acids Res (2001) 6.49
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet (1977) 5.10
Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol (1989) 4.53
Knowledge-based indexing of the medical literature: the Indexing Aid Project. J Am Soc Inf Sci (1987) 4.15
Technique to improve chronic motor deficit after stroke. Arch Phys Med Rehabil (1993) 3.50
Learning of visceral and glandular responses. Science (1969) 3.13
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet (1993) 3.03
Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res (1982) 3.02
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77
Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet (2001) 2.44
Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc Natl Acad Sci U S A (2001) 2.44
Cimetidine and HDL cholesterol. Lancet (1983) 2.40
The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J (2001) 2.21
Serum lipoproteins and susceptibility of men of Indian descent to coronary heart disease. The St James Survey, Trinidad. Lancet (1982) 2.11
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res (2000) 2.05
High total and cardiovascular disease mortality in adults of Indian descent in Trinidad, unexplained by major coronary risk factors. Lancet (1986) 2.04
Antithrombin III and arterial disease. Lancet (1991) 1.98
Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med (1994) 1.96
An operant approach to rehabilitation medicine: overcoming learned nonuse by shaping. J Exp Anal Behav (1994) 1.96
Letter: High-density lipoprotein and atherosclerosis. Lancet (1975) 1.93
C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis (2000) 1.90
Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J (1987) 1.88
Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J (1992) 1.88
Ethnic variation in forced expiratory volume and forced vital capacity of African and Indian adults in Guyana. Am Rev Respir Dis (1970) 1.87
Regulation of macrophage activation. Cell Mol Life Sci (2003) 1.83
Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J (Clin Res Ed) (1981) 1.80
Vigorous exercise in leisure time, coronary risk-factors, and resting electrocardiogram in middle-aged male civil servants. Br Heart J (1976) 1.69
Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem (2001) 1.65
Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol (1999) 1.63
Towards an improved lipid-lowering diet: additive effects of changes in nutrient intake. Lancet (1981) 1.61
The same normal cell protein is phosphorylated after transformation by avian sarcoma viruses with unrelated transforming genes. Mol Cell Biol (1981) 1.59
Interaction between high density and low density lipoproteins uptake and degradation by cultured human fibroblasts. J Clin Invest (1977) 1.58
Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res (1998) 1.57
TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res (2001) 1.55
Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol (1972) 1.50
Haemostatic changes that constitute the hypercoagulable state. Lancet (1991) 1.47
Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol (1994) 1.47
Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) (1985) 1.42
Common DNA polymorphism within coding sequence of apolipoprotein B gene associated with altered lipid levels. Lancet (1986) 1.41
Interactions between learned and physical factors in mental illness. Semin Psychiatry (1972) 1.40
The value of behavioral research on animals. Am Psychol (1985) 1.38
An assessment of lung volumes and gas transfer in sickle-cell anaemia. Thorax (1971) 1.38
Characteristics relevant to cardiovascular disease among adults of African and Indian origin in Guyana. Bull World Health Organ (1970) 1.37
The light-harvesting chlorpohyll-protein complex of photosystem II. Its location in the photosynthetic membrane. J Cell Biol (1976) 1.34
Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J (1987) 1.33
The lipoid pneumonia of blackfat tobacco smokers in Guyana. Q J Med (1971) 1.32
Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation (2001) 1.32
High density lipoproteins and atherosclerosis. Annu Rev Med (1980) 1.30
Lung function of healthy boys and girls in Jamaica in relation to ethnic composition, test exercise performance, and habitual physical activity. Thorax (1977) 1.30
HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. Am J Pathol (2001) 1.29
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum (2001) 1.27
Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet (2003) 1.27
High-density lipoprotein composition is altered by a common DNA polymorphism adjacent to apoprotein AII gene in man. Lancet (1985) 1.26
Histopathology of malignant lesions of the penis. Urol Clin North Am (1992) 1.25
Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet (1983) 1.24
Positive associations between single nucleotide polymorphisms in the IGF2 gene region and body mass index in adult males. Hum Mol Genet (2001) 1.23
Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis (1990) 1.22
Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature (1985) 1.22
Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res (2001) 1.20
Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med (2001) 1.19
Prevalence of ischaemic heart disease and associations with serum lipoproteins in subjects aged 45 to 64 years. The Speedwell study. Br Heart J (1982) 1.19
Molecular analysis of multifocal prostate cancer lesions. J Pathol (1999) 1.19
Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection. J Urol (1998) 1.18
Steroid hormone induction and expression patterns of L-plastin in normal and carcinomatous prostate tissues. Am J Pathol (1997) 1.18
Recognizing phosphatidylinositol 3-phosphate. Cell (2001) 1.18
Association between dietary fat intake and plasma factor VII coagulant activity--a predictor of cardiovascular mortality. Atherosclerosis (1986) 1.17
EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis (2005) 1.17
Modification of a visceral response, salivation in thirsty dogs, by instrumental training with water reward. J Comp Physiol Psychol (1967) 1.15
Suppression of immunity by stress: effect of a graded series of stressors on lymphocyte stimulation in the rat. Science (1981) 1.15
Stress-induced suppression of immunity in adrenalectomized rats. Science (1983) 1.14
The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia (2006) 1.14
Familial apolipoprotein CII deficiency: plasma lipoproteins and apolipoproteins in heterozygous and homozygous subjects and the effects of plasma infusion. Eur J Clin Invest (1981) 1.14
Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids. J Lipid Res (2001) 1.13
A community survey of respiratory disease among East Indian and African adults in Guyana. Thorax (1971) 1.12
Mental health services use by elderly adults in a primary care setting. J Gerontol (1987) 1.12
Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol (2000) 1.12
Influence of n-6 versus n-3 polyunsaturated fatty acids in diets low in saturated fatty acids on plasma lipoproteins and hemostatic factors. Arterioscler Thromb Vasc Biol (1997) 1.11
Comparison of the bronchial response to running and cycling in asthma using an improved definition of the response to work. Thorax (1975) 1.10
Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation (2000) 1.10
A common variant in the gene for lipoprotein lipase (Asp9-->Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol (1995) 1.09
Mechanical studies of the bone bioglass interfacial bond. J Biomed Mater Res (1975) 1.08
Relationships between plasma lipoprotein cholesterol concentrations and the pool size and metabolism of cholesterol in man. Atherosclerosis (1976) 1.08
Instrumental learning of vasomotor responses by rats: learning to respond differentially in the two ears. Science (1968) 1.08
An alternative procedure for incorporating radiolabelled cholesteryl ester into human plasma lipoproteins in vitro. Biochem J (1985) 1.08
Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation (1994) 1.07
The Tromsø Heart Study: serum apolipoprotein AI concentration in relation to future coronary heart disease. Eur J Clin Invest (1978) 1.07
Widely used prostate carcinoma cell lines share common origins. Prostate (2001) 1.04
A comparison of T-wave inversion, S-T elevation, and RS amplitudes in precordial leads of Africans and Indians in Guyana. Am Heart J (1971) 1.04
Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol (1997) 1.04
Instrumental learning of heart rate changes in curarized rats: shaping, and specificity to discriminative stimulus. J Comp Physiol Psychol (1967) 1.03
Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost (2001) 1.03